MRSA – Virulent New Strain USA600

Posted in These Categories: Studies and Hospital Acquired Infections

Medizone International, Inc. (Dually Traded: OTCBB/OTCQB: MZEI)
(http://medizoneint.com)

There is a lethal new strain of MRSA according to a study presented at the 47th annual meeting of the Infectious Diseases Society of America in Philadelphia. The study indicates 50 percent of patients who contracted the USA600 strain died within 30 days compared to only 11 percent of patients infected with different types of MRSA strain.

All deaths occurred within the first 15 days of infection.

The USA600 strain has distinctive qualities that could be linked to increased mortality rates.

The USA600 strain of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is potentially lethal and is associated with vancomycin resistance, according to a study from the Henry Ford Health System in Detroit. USA600 occurs mainly in older, sicker patients with more comorbidities. In the study, 38% of those with the strain were from nursing homes. Researchers looked at MRSA bloodstream infections at Henry Ford Hospital from 2005 to 2008. Of 420 blood stream infections, 16 were USA600-positive. Of the 16 patients with USA600, 80% failed (death within 30 days, positive blood cultures after 10 days, or new MRSA bloodstream infection within 30 days of treatment); and 20% got better. Mortality in patients with the USA600 strain was 50% (eight deaths), compared with 11% in those with non-USA600 MRSA.

Medizone International, Inc. is a research and development company engaged in developing its AsepticSure™ System to decontaminate and sterilize hospitals, sports training facilities, schools and other critical infrastructure. A government variant is being developed for bio-terrorism counter measures. Successful decontamination by AsepticSure™ to the 6 log standard or greater has been demonstrated with C.difficile, E coli, Pseudomonas aeruginous, MRSA, VRE and Bacillius subtilis.

Medizone International, Inc.
Post Office Box 742
Stinson Beach, CA 94970
Telephone: 415-868-0300
Fax: 415-868-2344

This release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.

Tweet This Post

Tags: MRSA USA600